Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Depreciation & Amortization (CF) (2016 - 2025)

Catalyst Pharmaceuticals' Depreciation & Amortization (CF) history spans 16 years, with the latest figure at $72000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 36.84% year-over-year to $72000.0; the TTM value through Dec 2025 reached $375000.0, down 5.54%, while the annual FY2025 figure was $375000.0, 5.54% down from the prior year.
  • Depreciation & Amortization (CF) reached $72000.0 in Q4 2025 per CPRX's latest filing, roughly flat from $72000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $116000.0 in Q2 2025 to a low of $31000.0 in Q2 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $71050.0, with a median of $76500.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 592.86% in 2021, then plummeted 64.95% in 2022.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $33000.0 in 2021, then increased by 6.06% to $35000.0 in 2022, then soared by 140.0% to $84000.0 in 2023, then soared by 35.71% to $114000.0 in 2024, then tumbled by 36.84% to $72000.0 in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Depreciation & Amortization (CF) are $72000.0 (Q4 2025), $72000.0 (Q3 2025), and $116000.0 (Q2 2025).